Zacks Research Upgrades Arvinas (NASDAQ:ARVN) to Strong-Buy

Arvinas (NASDAQ:ARVN) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

Other analysts also recently issued research reports about the company. Wall Street Zen upgraded Arvinas from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 26th. Stephens restated an “overweight” rating and set a $18.00 price objective on shares of Arvinas in a research report on Wednesday, June 3rd. Barclays upped their target price on Arvinas from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Weiss Ratings cut Arvinas from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. Finally, Citigroup lifted their price target on shares of Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Arvinas currently has a consensus rating of “Hold” and a consensus target price of $14.90.

Arvinas Stock Performance

NASDAQ ARVN opened at $8.68 on Wednesday. The firm has a 50-day simple moving average of $8.06 and a 200 day simple moving average of $10.25. Arvinas has a twelve month low of $6.05 and a twelve month high of $14.51. The stock has a market cap of $560.03 million, a PE ratio of 86.81 and a beta of 1.71.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, August 4th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $2.95. Arvinas had a return on equity of 1.91% and a net margin of 2.94%.The business had revenue of $249.70 million for the quarter, compared to the consensus estimate of $60.71 million. During the same period last year, the business earned ($0.84) earnings per share. The firm’s revenue for the quarter was up 1014.7% compared to the same quarter last year. Research analysts forecast that Arvinas will post -2.39 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Arvinas news, insider Noah Berkowitz sold 11,108 shares of Arvinas stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $9.94, for a total transaction of $110,413.52. Following the sale, the insider directly owned 191,395 shares of the company’s stock, valued at approximately $1,902,466.30. The trade was a 5.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Andrew Saik sold 11,139 shares of Arvinas stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $110,721.66. Following the sale, the chief financial officer directly owned 193,128 shares in the company, valued at $1,919,692.32. The trade was a 5.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 41,728 shares of company stock worth $402,649 over the last quarter. Company insiders own 7.30% of the company’s stock.

Institutional Trading of Arvinas

Institutional investors have recently bought and sold shares of the stock. ProShare Advisors LLC raised its stake in shares of Arvinas by 7.2% during the fourth quarter. ProShare Advisors LLC now owns 14,827 shares of the company’s stock worth $176,000 after buying an additional 993 shares during the last quarter. Intech Investment Management LLC boosted its stake in Arvinas by 3.6% in the third quarter. Intech Investment Management LLC now owns 32,653 shares of the company’s stock valued at $278,000 after acquiring an additional 1,125 shares during the last quarter. MetLife Investment Management LLC boosted its stake in Arvinas by 4.3% in the fourth quarter. MetLife Investment Management LLC now owns 33,810 shares of the company’s stock valued at $401,000 after acquiring an additional 1,381 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Arvinas by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after acquiring an additional 2,122 shares during the last quarter. Finally, Oxford Asset Management LLP grew its holdings in Arvinas by 15.5% during the 2nd quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock worth $123,000 after acquiring an additional 2,242 shares during the period. Institutional investors and hedge funds own 95.19% of the company’s stock.

Trending Headlines about Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Arvinas received a Zacks Rank #1 (Strong Buy), reflecting improved expectations for its earnings outlook and potentially supporting near-term buying interest. Arvinas Upgraded to Strong Buy
• Positive Sentiment: HC Wainwright materially raised its FY2026 EPS forecast to a loss of $0.67 from a loss of $3.98, while also improving estimates for FY2027 through FY2030. Its FY2030 forecast moved into profitability at $0.07 per share, suggesting better long-term operating prospects. Arvinas Analyst Estimates
• Positive Sentiment: BTIG Research assigned Arvinas a “Buy” rating, adding to the bullish analyst support. Arvinas Earns Buy Rating from BTIG
• Positive Sentiment: Arvinas’ latest quarterly results substantially exceeded expectations, with $249.7 million in revenue versus a $60.7 million consensus estimate and EPS of $2.58 versus an expected loss. Revenue increased more than tenfold year over year, providing a strong fundamental backdrop. Arvinas Trading Higher on Strong Earnings
• Neutral Sentiment: HC Wainwright lowered its Q3 and Q4 2026 EPS forecasts to losses of $1.20 and $1.19, respectively, but raised most full-year estimates. The mixed revisions indicate near-term profitability remains pressured even as the longer-term outlook improves.
• Negative Sentiment: Wells Fargo downgraded Arvinas to “Equal Weight,” signaling reduced conviction in additional upside and contributing to selling pressure. Arvinas Rating Lowered to Equal Weight
• Negative Sentiment: Shares fell sharply following an analyst downgrade, highlighting the stock’s sensitivity to changes in Wall Street sentiment. Arvinas Shares Down on Analyst Downgrade

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.